
Current Price | $7.77 | Mkt Cap | $271.0M |
---|---|---|---|
Open | $7.67 | P/E Ratio | 0.00 |
Prev. Close | $7.73 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $7.67 - $7.85 | Volume | 78,247 |
52-Wk Range | $2.37 - $9.91 | Avg. Daily Vol. | 477,823 |
The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer.
Current Price | $7.77 | Mkt Cap | $271.0M |
---|---|---|---|
Open | $7.67 | P/E Ratio | 0.00 |
Prev. Close | $7.73 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $7.67 - $7.85 | Volume | 78,247 |
52-Wk Range | $2.37 - $9.91 | Avg. Daily Vol. | 477,823 |
The best Bull and Bear pitches based on recency and number of recommendations.
CVM is expecting to conclude its phase III of Multikrine end 2014 or early 2015
Has it really been over a year since I looked at Cel-Sci? I knew my life was missing something. Catching up was very entertaining. Things are as scuzzy and futile as ever over at Cel-Sci.Last February I pointed out that the company's claim of being… More
Read the most recent pitches from players about CVM.
Recs
I've studied the statistic on this from public information for a long time, the odds are highly in favor of a successful clinical trial with staggering consequences.
Recs
https://velociraptor.cc
Recs
They will fail their Phase III trial
Find the members with the highest scoring picks in CVM.
jeepdrew222 (69.75) Score: +323.71
The Score Leader is the player with the highest score across all their picks in CVM.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
jeepdrew222 | 69.75 | 8/28/2018 |
![]() |
5Y | $1.80 | +331.67% | +7.96% | +323.71 | 0 Comment | |
dexxyru | < 20 | 9/24/2009 |
![]() |
5Y | $397.50 | -98.05% | +198.23% | +296.28 | 0 Comment | |
DarthMaul09 | 29.08 | 10/16/2009 |
![]() |
5Y | $387.50 | -97.99% | +188.06% | +286.06 | 4 Comments | |
pennycruncher | < 20 | 10/19/2009 |
![]() |
5Y | $380.00 | -97.96% | +187.35% | +285.30 | 0 Comment | |
bermuda999 | 25.02 | 8/16/2010 |
![]() |
1Y | $125.25 | -93.80% | +191.35% | +285.15 | 0 Comment | |
arboretum | 28.71 | 6/14/2010 |
![]() |
5Y | $125.00 | -93.78% | +183.58% | +277.36 | 0 Comment | |
qasamm | < 20 | 1/3/2011 |
![]() |
3M | $209.88 | -96.30% | +147.34% | +243.64 | 0 Comment | |
caelin389 | 52.72 | 5/17/2018 |
![]() |
5Y | $2.82 | +175.53% | +15.09% | +160.44 | 0 Comment | |
Rollme | < 20 | 10/8/2013 |
![]() |
5Y | $21.48 | -63.82% | +88.55% | +152.37 | 0 Comment | |
remrem44 | < 20 | 3/14/2014 |
![]() |
3Y | $34.17 | -77.26% | +69.16% | +146.42 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.